Quanterix
About Quanterix
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
Company Metrics
- Employees: 251-500
- Monthly Visits: 10507
- Tech Stack: 36 active products
Financial Information
- Estimated Revenue: $10M to $50M
- Total Funding: 533299999 USD
- Last Funding: None (Grant)
- Funding Status: IPO
Technology Stack
Quanterix actively uses 36 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Health Diagnostics, Life Science, Pharmaceutical
Headquarters: Billerica, Massachusetts, United States
Leadership
- Samira Amini - SVP, Finance Ops & Chief of Staff to CEO LinkedIn
- Sibu Tshabalala - Senior Director, IT Business Partner Functions LinkedIn
- David Duffy - Chief Technology Officer and Vice President of Research LinkedIn
- Alexandra Phillips - SVP and Chief Information Officer LinkedIn
- Erica Bell - SVP, Chief People Officer LinkedIn
Employees
- Ahmed Hassan - Talent Acquisition Partner (LinkedIn)
- Daniel Pikora - Chief Operating Officer (LinkedIn)
- Darrin Crisitello - Chief Commercial Officer (CCO) (LinkedIn)
- Masoud Toloue - Chief Executive Officer (LinkedIn)
- Mike Doyle - Chief Financial Officer (LinkedIn)